MetaStat Stock

MetaStat CROIC

The Cash Return on Invested Capital (CROIC) of MetaStat (MTST) as of Sep 5, 2026 is 505.37 %. In the previous year, Cash Return on Invested Capital (CROIC) was 128.90 % — a change of 292.08% (higher).

CROIC

505.37 %

YoY

292.08%

Last updated:

Cash Return on Invested Capital (CROIC) of MetaStat is 2026 505.37 % . Cash Return on Invested Capital (CROIC) of MetaStat was 2025 128.90 % . It decreases by 292.08% higher compared to the previous year.

The MetaStat CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2014
-600.71 USD
Jan 1, 2015
-712.43 USD
Jan 1, 2016
1,390.92 USD
Jan 1, 2017
128.90 USD
Jan 1, 2018
505.37 USD
The MetaStat CROIC history
YEARCROICYoY
505.37 %+292.08%
128.90 %-90.73%
1,390.92 %-295.24%
-712.43 %+18.60%
-600.71 %
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

Cash Return on Invested Capital (CROIC) of MetaStat is 505.37 % in 2026.

Cash Return on Invested Capital (CROIC) of MetaStat changed from 128.90 % to 505.37 %, representing a 292.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) MetaStat since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s MetaStat with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — MetaStat

All Key Metrics — MetaStat